Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Lymphoma/Leukemia

This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. JZP458 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving DA-EPOCH with or without rituximab plus JZP458 may kill more cancer cells in patients with newly diagnosed Ph negative B-ALL or T-ALL.

开始日期2025-06-01

申办/合作机构

University of Washington

[+1]

NCT06692452

/ Not yet recruiting临床2期IIT

A Phase II Study of Tazemetostat in Combination with CHOP for Previously Untreated T Cell Lymphoma

This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL).
The name of the study drugs involved in this study are:
* Tazemetostat (a type of inhibitor for Enhancer of Zeste Homolog 2 (EZH2))
* Standard of care CHOP therapy:
* Cyclophosphamide (a type of alkylating agent)
* Doxorubicin (a type of anthracycline antibiotic)
* Vincristine (a type of vinca alkaloid)
* Prednisone (a type of corticosteroid)
* Standard of care BEAM conditioning regimen for autologous stem cell transplant:
* Carmustine (a type of alkylating agent)
* Etoposide (a type of Topoisomerase II inhibitor)
* Cytarabine (a type of antineoplastic)
* Melphalan (a type of alkylating agent)

开始日期2025-04-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

NCT06401330

/ Not yet recruiting临床3期IIT

Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.

开始日期2025-03-31

申办/合作机构

The Children's Oncology Group Foundation, Inc.

100 项与依托泊苷相关的临床结果

登录后查看更多信息

100 项与依托泊苷相关的转化医学

登录后查看更多信息

100 项与依托泊苷相关的专利（医药）

登录后查看更多信息

35,092

项与依托泊苷相关的文献（医药）

2025-04-01·MECHANISMS OF AGEING AND DEVELOPMENT

Mangiferin protects mesenchymal stem cells against DNA damage and cellular aging via SIRT1 activation

Article

作者: Cho, Gwang-Won ; Lim, Gyeong Min

The protective effects of mangiferin (MAG) against etoposide- and high glucose (HG)-induced DNA damage and aging were investigated in human bone marrow-mesenchymal stem cells (hBM-MSCs). Etoposide, a topoisomerase II inhibitor, was used to induce double-strand breaks (DSBs) in hBM-MSCs, resulting in increased genotoxicity, elevated levels of the DNA damage sensor ATM and CDKN1A, and decreased levels of the aging markers H3 and H4. MAG activated AMPK and SIRT1, thus protecting against DSB-induced damage. Following long-term exposure to HG, MAG significantly mitigated DNA damage and delayed cellular aging, as evidenced by the preservation of H3, H4, LMNB1, and SIRT1 mRNA levels and reduction in γ-H2AX foci and DSBs. Furthermore, MAG improved genome stability, as indicated by decreased LINE1 expression and increased levels of the heterochromatin marker TRIM28, thereby maintaining H3K9me3 levels. MAG and metformin treatment enhanced cell proliferation, reduced senescence-associated β-galactosidase staining, and lowered the levels of the senescence-associated secretory phenotype factors IL-1A, IL-1B, IL-6, IL-8, CCL2, and CCL20 and senescence marker CDKN1A, CDKN2A and p53. MAG may reduce DNA damage and delay aging in hBM-MSCs under HG conditions, highlighting their potential as therapeutic agents for aging-related diseases.

2025-03-01·PEDIATRIC BLOOD & CANCER

Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study‐5 and Children's Oncology Group Study AREN0321

Article

作者: Renfro, Lindsay A. ; Daw, Najat C. ; Geller, James I. ; Dome, Jeffrey S. ; Warwick, Anne B. ; Tochner, Zelig ; Paulino, Arnold ; Gow, Kenneth ; Hoffer, Fredric A. ; Gratias, Eric ; Anderson, James R. ; Fernandez, Conrad V. ; Ward, Deborah A. ; Biegel, Jackie ; Ehrlich, Peter F. ; Mullen, Elizabeth A. ; Huff, Vicki ; Kalapurakal, John A. ; Grundy, Paul E. ; Perlman, Elizabeth J.

ABSTRACT:

Purpose:

National Wilms Tumor Study‐5 (NWTS‐5) and AREN0321 evaluated the outcomes of children with rhabdoid tumor of the kidney (RTK) and malignant rhabdoid tumor of soft tissues (MRT).

Patients and Methods:

Eligible patients with RTK were enrolled prospectively on NWTS‐5 (1995–2002) and treated with carboplatin and etoposide alternating with cyclophosphamide (Regimen RTK). Patients with RTK or MRT were enrolled on AREN0321 (2005–2012) and received vincristine, doxorubicin, and cyclophosphamide alternating with carboplatin, cyclophosphamide, and etoposide (Regimens UH‐1 or dose‐reduced Revised UH‐1). We report event‐free survival (EFS) and overall survival (OS) from each study.

Results:

Thirty patients received Regimen RTK on NWTS‐5; on AREN0321, 20 received UH‐1 and 19 received Revised UH‐1. Patient and disease characteristics were statistically similar between studies. Patients on AREN0321 had significantly improved EFS and OS compared to those on NWTS‐5 (4‐year EFS = 23.1% vs. 16.7%; p = 0.020; 4‐year OS = 30.6% vs. 20.0%; p = 0.014), mostly driven by patients with Stage I/II disease (p = 0.05). Median time to an event was 3.6 months on NWTS‐5 compared to 7.2 months on AREN0321. There were no differences in EFS or OS by revised versus original Regimen UH‐1 on AREN0321, or by renal versus extra‐renal primary disease when the studies were pooled.

Conclusions:

The more intensive treatment regimen used on AREN0321 improved EFS and OS overall, a result driven by patients with Stage I/II disease. Despite this improvement, outcomes for patients with rhabdoid tumor remain unsatisfactory and there is a need for novel therapeutic strategies.

2025-03-01·BIOORGANIC CHEMISTRY

New N-Alkylketonetetrahydroisoquinoline derivatives exhibits antitumor effect by HA-CD44 interaction inhibition in MDA-MB-231 breast cancer

Article

作者: Sánchez-Martín, Rosario M ; Cruz-López, Olga ; Huertas-Camarasa, Felipe ; Erviti-Marticorena, Laura ; Chayah, Meriem ; Conejo-García, Ana ; Domene, Carmen ; Espejo-Román, Jose M

Molecular interactions at the cell surface, in particular between hyaluronic acid (HA) and the cluster of differentiation 44 (CD44) receptor, are crucial in several biological processes and diseases such as cancer. Thus, inhibition of the HA-CD44 interaction has become a promising therapeutic strategy. Etoposide was the only antitumor compound known to inhibit the binding of CD44 to HA, thereby disrupting key functions that drive malignancy. However, our recent research led to the development of N-alkyl and N-aryl THIQ derivatives, which represented a significant advancement in this field. Here, we further explore the structure-activity relationships of a series of newly designed N-alkylcarbonyl THIQ and study the structural parameters that define both the CD44 inhibitory and antiproliferative activities. Compounds 5d and 7d showed the most improvement of the antiproliferative activity compared to the N-alkylketone 1. Cell viability, competitive binding assays and molecular dynamics studies demonstrated effective inhibition of HA-CD44 binding by compounds 5d and 7d. This work not only expands the arsenal of potential therapeutic agents targeting HA-CD44 interactions but also highlights the potential for new treatments that could more effectively disrupt cancer progression.

642

项与依托泊苷相关的新闻（医药）

2025-02-06

·医药观澜

复宏汉霖抗PD-1单抗在欧盟获批上市，一线治疗广泛期小细胞肺癌

▎药明康德内容团队报道 2月5日，复宏汉霖宣布，抗PD-1单抗斯鲁利单抗（H药，欧洲商品名：Hetronifly）正式获得欧盟委员会（EC）批准，联合卡铂和依托泊苷用于广泛期小细胞肺癌（ES-SCLC）成人患者的一线治疗。复宏汉霖新闻稿表示，这标志着H药成为首个在欧盟获批上市用于广泛期小细胞肺癌治疗的抗PD-1单抗。 2023年，复宏汉霖与Intas达成合作，授权其H药在欧洲和印度共50多个国家的独家开发和商业化权益。本次获批覆盖欧盟全部27个成员国以及欧洲经济区国家挪威、冰岛和列支敦士登，该区域的商业化将由Intas子公司Accord负责。 H药为重组人源化抗PD-1单抗注射液，已在中国、欧盟以及多个东南亚国家获批上市。截至目前，H药已在中国获批用于治疗鳞状非小细胞肺癌、广泛期小细胞肺癌、食管鳞状细胞癌和非鳞状非小细胞肺癌。小细胞肺癌（SCLC）占肺癌总数的15%-20%，具有恶性程度高、转移早、疾病进展迅速等特点，预后极差。SCLC分为局限期和广泛期，其中约30%-40%的患者确诊时处于局限期，其余处于广泛期。2022年12月，H药治疗SCLC获得EC授予的孤儿药资格；2024年9月，欧洲药品管理局（EMA）人用药品委员会（CHMP）发布推荐Hetronifly在欧盟获批上市积极意见。本次H药获EC批准主要基于ASTRUM-005研究，ASTRUM-005研究是一项随机、双盲、安慰剂对照的国际多中心3期研究，旨在评估斯鲁利单抗联合化疗对比安慰剂联合化疗用于ES-SCLC一线治疗的疗效和安全性。ASTRUM-005临床试验结果于2022年美国临床肿瘤学会（ASCO）年会以口头报告方式首次发布，并于《美国医学会杂志》（JAMA）发表。ASTRUM-005研究数据显示，截至2021年10月22日，斯鲁利单抗组的中位总生存期（OS）达到15.4个月，相比安慰剂组的10.9个月有明显延长。同时，斯鲁利单抗组的24个月总生存率达到43.1%（vs 7.9%），经独立影像评估委员会（IRRC）依据RECIST v1.1评估的中位无进展生存期（PFS）为5.7个月（vs 4.3个月）。基于ASTRUM-005研究，H药已陆续在中国、东南亚多国和欧盟获批用于一线治疗ES-SCLC。此外，复宏汉霖正在美国开展一项H药用于ES-SCLC的桥接试验，以进一步支持H药在美国的上市申报。参考资料： [1]汉霖头条 | 复宏汉霖H药汉斯状®于欧盟获批上市，用于一线治疗广泛期小细胞肺癌.Retrieved Feb 5, 2025, from https://mp.weixin.qq.com/s/ahVp4Wk7cxXKmvh1o_194Q 本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

上市批准临床3期ASCO会议临床结果免疫疗法

2025-02-06

·PRNewswire

Accord Healthcare: Hetronifly® (Serplulimab) receives Marketing Authorisation from the European Commission (EC), for the treatment of Extensive-Stage Small Cell Lung Cancer (ES- SCLC)

Hetronifly is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC (in combination with carboplatin and etoposide). Hetronifly is the only anti-PD-1 mAb approved in Europe for the treatment of ES-SCLC and is already approved in China, and several Southeast Asian countries. In December 2022, Hetronifly received orphan drug designation from the EC for the treatment of SCLC, which was renewed in 2025. The European Society for Medical Oncology (ESMO) scores serplulimab 4 out of 5 on their magnitude of clinical benefit scale (MCBS) in ES-SCLC. LONDON, Feb. 6, 2025 /PRNewswire/ -- Accord Healthcare Limited (Accord) announced today that the anti-PD-1 mAb, serplulimab, marketed as Hetronifly® in Europe, has been officially approved by the European Commission (EC) for use in combination with carboplatin and etoposide as a first-line treatment for ES-SCLC. This makes it the first anti-PD-1 monoclonal antibody to be approved in Europe for the treatment of ES-SCLC. Serplulimab was originated by Henlius Biotech. In 2023, Henlius entered into a collaboration with Intas Pharmaceuticals, granting Intas exclusive rights to develop and commercialise serplulimab in over 50 countries across Europe and India. This latest approval covers all 27 EU member states as well as the European Economic Area countries, including Norway, Iceland, and Liechtenstein. Commercialisation in Europe will be led by Accord. In December 2022, serplulimab received orphan drug designation from the EC for the treatment of SCLC, this was recently reviewed by the committee and renewed. ESMO scores serplulimab 4 out of 5 on their magnitude of clinical benefit scale (MCBS) in ES-SCLC. Welcoming the news Paul Tredwell, Executive Vice-President, EMENA, Accord Healthcare said: "At Accord, we are committed to transforming the lives of patients, and this approval of Hetronifly allows us to provide a much-needed new treatment option for patients with extensive stage small cell lung cancer. It also underlines our dedication to building our speciality business and driving innovation in oncology; a therapy area we have huge heritage in. "With our partners at Henlius, we can now have confidence that some of the most unwell lung cancer patients can benefit, giving them more precious time with their families and loved ones. Together, we will continue to collaborate to expand our pipeline of innovative medicines, further underlying our commitment to developing speciality medicines to provide a real difference to patients' lives in Europe and beyond." About Serplulimab Serplulimab (recombinant humanised anti-PD-1 monoclonal antibody injection)) is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in China and several SEA countries. Serplulimab has been approved by the National Medicinal Products Administration (NMPA) in China for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsNSCLC). Serplulimab was granted orphan drug designations by the FDA and the EC for the treatment of SCLC, and its bridging head-to-head trial in the United States to compare serplulimab to standard of care atezolizumab (anti-PD-L1 mAb) for the first-line treatment of ES-SCLC is well under way. The results of 4 pivotal trials of serplulimab were published in the Journal of the American Medical Association (JAMA), Nature Medicine, Cancer Cell and British Journal of Cancer, respectively. Furthermore, serplulimab was respectively recommended by the CSCO Guidelines for Small Cell Lung Cancer, the CSCO Guidelines for Non-Small Cell Lung Cancer, the CSCO Guidelines for Esophageal Cancer, the CSCO Clinical Practice Guidelines on Immune Checkpoint Inhibitor, the China Guidelines for Radiotherapy of Esophageal Cancer, and other definitive guides, providing valuable references for clinical diagnosis and treatment of tumours. About Lung Cancer Lung cancer is the most common cancer worldwide in terms of incidence and mortality. According to GLOBOCAN 2022, there were over 2.48 million new cases of lung cancer globally in 2022, accounting for 12.4% of all new cancer cases.1 Small cell lung cancer (SCLC), which accounts for 15% to 20% of all lung cancers, is characterised by high malignancy, early metastasis, rapid progression, and poor prognosis. Among SCLC patients, approximately 30% to 40% are diagnosed at a limited stage, while the remaining cases are in extensive stage. Within Europe, the prevalence of SCLC ranges from 1 to 5 per 10,000 people.2 References Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834 Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(7):839-853. doi:10.1016/j.annonc.2021.03.207 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准孤儿药引进/卖出免疫疗法

2025-02-06

·复星医药

复星医药自研创新药抗PD-1单抗汉斯状®欧盟获批上市，用于一线治疗广泛期小细胞肺癌

汉斯状®是全球首个获批一线治疗ES-SCLC的抗PD-1单抗。汉斯状®是首个且唯一在欧盟获批上市用于ES-SCLC治疗的抗PD-1单抗。汉斯状®目前已在中国、欧洲和东南亚多个国家获批上市，惠及超过90,000位患者。 2025年2月5日，复星医药（600196.SH；02196.HK）宣布，控股子公司复宏汉霖（02696.HK）自主研发的抗PD-1单抗斯鲁利单抗注射液（欧盟商品名：Hetronifly®，中国境内商品名：汉斯状®）联合卡铂和依托泊苷用于广泛期小细胞肺癌（ES-SCLC）成人患者一线治疗的上市许可申请（MAA）于近日获欧盟委员会（即European Commission）批准。据此，该药品获得所有欧盟成员国及冰岛、列支敦士登和挪威（分别为欧洲经济区国家）的集中上市许可，并成为首个且唯一在欧盟批准用于广泛期小细胞肺癌（ES-SCLC）治疗的抗PD-1单抗。截至目前，汉斯状®于中国境内（不包括港澳台地区）获批的适应症包括联合化疗一线治疗鳞状非小细胞肺癌（NSCLC）、广泛期小细胞肺癌（ES-SCLC）、食管鳞状细胞癌（ESCC）及非鳞状非小细胞肺癌（nsNSCLC）；亦已分别于欧盟、印度尼西亚、柬埔寨、泰国获批上市。此外，另有以汉斯状®为核心的多项联合疗法正在全球多个国家和地区开展临床试验。汉斯状®是全球首个获批一线治疗小细胞肺癌的PD-1抑制剂。以临床需求为导向，复宏汉霖就H药进行了差异化、多维度布局，聚焦肺癌、消化道肿瘤等高发大癌种，在全球范围内累计入组逾4800名受试者。 2023年，复宏汉霖与Intas达成合作，授权其H药在欧洲和印度共50多个国家的独家开发和商业化权益。本次获批覆盖欧盟全部27个成员国以及欧洲经济区国家挪威、冰岛和列支敦士登，该区域的商业化将由Intas子公司Accord负责。复星医药作为一家植根中国、创新驱动的全球化医药健康产业集团，坚持创新驱动，围绕未被满足的临床需求，重点强化抗体/ADC、细胞治疗、小分子等核心技术平台。作为复星医药重要的抗体技术平台，复宏汉霖在生物制药领域持续深化创新研发、不断扩展境内外市场、进一步增强全球竞争力，实现高质量发展。本次汉斯状®欧盟获批，标志着复星医药在全球创新药物研发和商业化方面迈出了重要一步，将进一步拓展该药品的全球市场区域获批，有望为全球肺癌患者提供新的治疗选择。 01 突破创新，聚焦未尽临床需求肺癌是全球发病率和死亡率最高的癌症，据GLOBOCAN最新数据显示，2022年全球约有超过248万新发肺癌病例，占癌症新发病例的12.4%[1]。小细胞肺癌（SCLC）占肺癌总数的15%-20%，具有恶性程度高、转移早、疾病进展迅速等特点，预后极差。 SCLC分为局限期和广泛期，其中约30%-40%的患者确诊时处于局限期，其余处于广泛期。欧盟SCLC的患者比例约为人口总数万分之一至五[2]。 2022年12月，H药治疗SCLC获得EC授予的孤儿药资格认定，有助于H药用于治疗SCLC在欧盟研发、注册及商业化等方面享受一定的政策支持。 2024年9月，欧洲药品管理局（EMA）人用药品委员会（CHMP）发布推荐Hetronifly®在欧盟获批上市积极意见。本次H药获EC批准主要基于ASTRUM-005研究，ASTRUM-005研究是一项随机、双盲、安慰剂对照的国际多中心III期研究，旨在评估斯鲁利单抗联合化疗对比安慰剂联合化疗用于ES-SCLC一线治疗的疗效和安全性。该试验在中国、欧盟波兰、土耳其、格鲁吉亚等多个国家共开设128个试验中心，入组585例受试者，其中约31.5%为白人。 ASTRUM-005临床试验结果于2022年美国临床肿瘤学会（ASCO）年会以口头报告方式首次发布，并于全球四大顶级医学期刊之一的《美国医学会杂志》（JAMA）发表，成为全球首个登上JAMA主刊的SCLC免疫治疗临床研究。基于ASTRUM-005研究，H药已陆续在中国、东南亚多国和欧盟获批用于一线治疗ES-SCLC，成为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗。此外，一项H药对比一线标准治疗阿替利珠单抗用于ES-SCLC的头对头桥接试验正在美国开展，以进一步支持H药在美国的上市申报。 02 全球布局，助力更多患者获益复宏汉霖长期对产品质量的严格要求亦为此次H药获EC批准奠定重要基础。 2023年，H药相关生产场地和设施顺利通过欧盟GMP（Certificate of GMP Compliance of a Manufacturer）检查并获得欧盟GMP证书，为H药稳定、高质供应欧洲市场提供保障。徐汇基地、松江基地（一）及松江基地（二）三个生产基地现有商业化总产能已达48,000升，实现全球产品常态化供应，全面覆盖中国、欧洲、拉丁美洲、中东北非、北美及东南亚。复宏汉霖现已建立一套符合国际质量标准的质量管理体系，覆盖从项目研发到物料管理、产品生产、质量控制、产品供应链管理以及产品上市后跟踪的全生命周期。此前，相关商业化生产基地及配套的质量管理体系已通过中国国家药监局、欧洲药品管理局（EMA）、美国食药监局（FDA）、欧盟质量受权人（QP）以及国际商业合作伙伴进行的多项实地核查及审计，获得中国、欧盟和美国GMP认证。 [1] Bray F、Laversanne M、Sung H 等人。2022 年全球癌症统计数据：GLOBOCAN 估计全球 185 个国家/地区 36 种癌症的发病率和死亡率。CA 癌症 J Clin。2024;74(3):229-263.doi：10.3322/caac.21834 [2] Dingemans AC， Früh M， Ardizzoni A， et al.小细胞肺癌：ESMO 临床实践指南，用于诊断、治疗和随访☆。安·昂科尔。2021;32(7):839-853.doi：10.1016/j.annonc.2021.03.207

上市批准抗体药物偶联物细胞疗法免疫疗法医药出海

100 项与依托泊苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00125	依托泊苷	L01CB01	DB00773

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
膀胱癌	日本	Clinigen Ltd.	1987-04-30
白血病	日本	Clinigen Ltd.	1987-04-30
淋巴瘤	日本	Nippon Kayaku Co., Ltd.	1987-03-31
卵巢癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
宫颈癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
小细胞肺癌	美国	Corden Pharma Latina SpA	1983-11-10
睾丸肿瘤	美国	Corden Pharma Latina SpA	1983-11-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
铂耐药性卵巢癌	临床3期	中国	江苏恒瑞医药股份有限公司	2019-08-16
原发部位不明恶性肿瘤	临床3期	美国	Pharmacia & Upjohn, Inc.	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	AstraZeneca PLC	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	Eli Lilly & Co.	2003-09-01
广泛期小细胞肺癌	临床3期	美国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	中国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	奥地利	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	比利时	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	巴西	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	保加利亚	GSK Plc	2001-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04294641 (CTgov)	临床2期	慢性移植物抗宿主病	10	Ibrutinib	蓋蓋醖夢憲憲膚鬱醖鹽(蓋糧艱築願選簾鑰蓋憲) = 鹽製襯衊鏇夢鏇積鹹繭獵願憲願衊願醖淵窪淵 (鏇顧觸鬱願淵淵壓糧構, 窪獵獵願憲簾淵廠範製 ~ 範膚鬱簾觸構餘製齋憲) 更多	-	2025-01-22
NCT03980925 (GETNE T1913, CTgov)	临床2期	胃肠道神经内分泌肿瘤 \| 胃肠胰神经内分泌肿瘤	37	Nivolumab+Etoposide+Carboplatin	蓋製糧顧顧顧夢憲窪糧(糧獵鏇淵鑰選膚願積構) = 簾構廠襯鹹夢範廠繭鏇選壓壓餘廠窪鏇壓憲餘 (築構鬱鹹範憲襯積簾鹹, 顧遞願顧衊遞繭糧構憲 ~ 夢鬱廠廠網餘壓窪築繭) 更多	-	2025-01-13
NCT02705508 (Pubmed \| Hematology) 人工标引	临床2期	结外NK-T细胞淋巴瘤一线	34	PEG (pegaspargase, etoposide, gemcitabine)	繭壓積餘獵鏇艱艱齋獵(選醖窪壓憲襯製膚醖簾) = 醖鹹夢繭築網齋鬱鏇夢壓廠壓鏇顧願製艱範餘 (遞襯壓構積廠構簾鹽鑰 ) 更多	积极	2024-12-31
NCT04923776 (CTgov)	临床2期	广泛期小细胞肺癌	2	Stereotactic Body Radiation Therapy (SBRT)+Etoposide+Carboplatin+Atezolizumab	鏇鏇鏇蓋鹹膚築蓋衊製(夢廠艱構淵範膚觸衊觸) = 鑰顧壓獵膚鹹襯簾積築顧鏇繭鏇鹽鹹憲繭鏇廠 (襯構願觸餘鏇繭繭範鏇, 鹹觸齋廠壓艱鏇獵範糧 ~ 製願窪淵鑰襯壓壓衊鹽) 更多	-	2024-12-30
NCT00801216 (SCNSL1, CTgov)	临床2期	中枢神经系统疾病 \| B细胞淋巴瘤	40	etoposide+cyclophosphamide+carmustine+Rituximab+methotrexate+Thiotepa+cytarabine	鬱顧鏇顧淵築簾襯夢壓(鬱願製繭築築艱膚鑰廠) = 夢艱衊窪鹽襯廠製糧壓鹽遞壓製選構觸艱餘顧 (糧製範鏇鏇觸壓窪衊製, 糧鏇鹽憲廠鏇艱繭鹽憲 ~ 遞餘積遞簾鏇構膚積壓) 更多	-	2024-12-10
ASH2024	N/A	多发性骨髓瘤	-	Etoposide + G-CSF	膚膚築衊鏇艱鹹鹽範窪(顧廠衊簾築繭願構築鹹) = The primary adverse events were grade III-IV bone marrow suppression (100%) and febrile neutropenia (22.7%), with no documented bloodstream infections or hepatorenal toxicity 壓範衊襯齋遞淵蓋遞膚 (醖齋鹹糧遞壓觸艱壓簾 )	-	2024-12-07
ESMO_ASIA2024	N/A	广泛期小细胞肺癌一线	274	Cisplatin (CDDP)+Etoposide (ETP)+Durvalumab (DUR)	範構夢齋鬱醖顧鹽製衊(淵範蓋觸蓋簾願夢獵繭) = 8% vs. 4% 鑰艱鬱膚憲築網鬱糧衊 (齋繭積鏇壓醖願製膚願 ) 更多	积极	2024-12-07
ESMO_ASIA2024	N/A	广泛期小细胞肺癌一线	274	Carboplatin (CBDCA)+ETP+Atezolizumab (ATZ)		积极	2024-12-07
NCT04951115 (CTgov)	临床2期	小细胞肺癌	6	Stereotactic Body Radiotherapy+Etoposide+Carboplatin+Cisplatin+Durvalumab	壓遞製壓繭壓願齋艱鑰(淵遞壓獵夢壓憲網蓋願) = 廠鑰蓋壓觸壓製憲淵製廠齋餘糧鬱糧鹽蓋網獵 (夢壓鏇憲獵築窪廠鑰製, 觸網蓋廠襯範選築蓋鹽 ~ 網鹹獵鑰齋糧夢選窪顧) 更多	-	2024-11-26
NCT03923179 (ESMO2024) 人工标引	临床2期	HER2阳性转移性乳腺癌 HER2 Positive	22	Pyrotinib 400mg per dayetoposide	獵觸製選繭廠鹽壓蓋廠(衊淵窪窪糧鬱鹹鏇憲範) = 糧鬱糧鏇淵壓顧憲醖鏇獵觸遞網餘鏇獵製鬱選 (製觸鹹築積鹽襯夢遞鑰, 7.6 ~ 10.4) 更多	积极	2024-09-16
ESMO2024 人工标引	N/A	弥漫性大B细胞淋巴瘤 G6PD deficiency	82	RituximabCyclophosphamideDoxorubicin HydrochlorideVincristine SulfatePrednisone	襯簾鏇範簾壓壓願繭繭(願壓鹹膚獵範獵鬱顧膚) = 廠蓋憲廠艱製艱遞憲鹹齋醖糧願襯廠鏇簾齋襯 (廠構壓餘鹹積鏇顧窪鹽 ) 更多	不佳	2024-09-15
ESMO2024 人工标引	N/A	弥漫性大B细胞淋巴瘤 G6PD deficiency	82	RituximabCyclophosphamideEtoposideVincristine SulfatePrednisone	襯簾鏇範簾壓壓願繭繭(願壓鹹膚獵範獵鬱顧膚) = 膚廠窪衊選鑰獵鹽構繭齋醖糧願襯廠鏇簾齋襯 (廠構壓餘鹹積鏇顧窪鹽 ) 更多	不佳	2024-09-15